AbbVie (NYSE:ABBV) Stock Unloaded Rep. Lisa C. McClain

Key Points

• Representative Lisa C. McClain sold shares of AbbVie Inc. (NYSE:ABBV), disclosing a sale of between $1,001 and $15,000 on July 22nd, as part of various recent stock transactions.
• AbbVie reported disappointing quarterly earnings, with $2.97 earnings per share (EPS) falling short of analysts' expectations of $3.24, although its revenue exceeded expectations at $15.42 billion.
• The company announced a quarterly dividend of $1.64 per share, yielding 3.2%, with a dividend payout ratio indicating it pays out more in dividends than it earns.

Representative Lisa C. McClain (R-Michigan) recently sold shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

AbbVie Stock Performance

AbbVie stock traded down $0.5130 during trading on Tuesday, reaching $206.0570. The company had a trading volume of 1,533,565 shares, compared to its average volume of 6,672,959. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $218.66. The firm's 50-day simple moving average is $191.42 and its 200 day simple moving average is $192.47. The firm has a market capitalization of $364.01 billion, a price-to-earnings ratio of 98.09, a price-to-earnings-growth ratio of 1.33 and a beta of 0.50. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. During the same period in the prior year, the business posted $2.65 earnings per share. AbbVie's revenue for the quarter was up 6.6% compared to the same quarter last year. Sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were issued a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend was Tuesday, July 15th. AbbVie's dividend payout ratio is presently 312.38%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. This trade represents a 19.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the sale, the executive vice president directly owned 58,247 shares in the company, valued at approximately $11,562,611.97. The trade was a 18.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.08% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ABBV. BNP Paribas upgraded AbbVie to a "hold" rating in a research report on Thursday, May 8th. Bank of America lifted their price target on AbbVie to $204.00 and gave the stock a "hold" rating in a research report on Monday, June 9th. Raymond James Financial raised their price objective on shares of AbbVie from $227.00 to $236.00 and gave the stock an "outperform" rating in a research note on Friday, August 1st. Citigroup lifted their price target on shares of AbbVie to $205.00 and gave the company a "hold" rating in a research note on Wednesday, June 11th. Finally, Guggenheim lifted their price target on shares of AbbVie from $216.00 to $227.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Five investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $214.95.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Steel Grove Capital Advisors LLC grew its stake in shares of AbbVie by 1.7% in the 4th quarter. Steel Grove Capital Advisors LLC now owns 3,110 shares of the company's stock valued at $553,000 after buying an additional 52 shares during the period. FF Advisors LLC raised its holdings in shares of AbbVie by 3.6% in the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company's stock valued at $286,000 after purchasing an additional 53 shares in the last quarter. Landaas & Co. WI ADV raised its holdings in shares of AbbVie by 1.1% in the 2nd quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company's stock valued at $920,000 after purchasing an additional 53 shares in the last quarter. Bernardo Wealth Planning LLC raised its stake in AbbVie by 2.9% during the 2nd quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company's stock worth $354,000 after acquiring an additional 53 shares in the last quarter. Finally, Private Management Group Inc. raised its stake in AbbVie by 1.9% during the 1st quarter. Private Management Group Inc. now owns 2,938 shares of the company's stock worth $616,000 after acquiring an additional 54 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.